Ø 001

APR 2 0 2007

VIA FACSIMILE 571-273-8300 7 Pages Total

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL					Attorney's Docket No: 2852-US-CNT				
Serial No.		Filing Da		Examiner		Group A			
10/802,1	133	Marc	h 16, 2004	Eileen B. O	HARA		164	0	
In Re Application of Dirk M. ANDERSON									
For ANTIBODIES AGAINST RANK LIGAND (as amended)									
TO THE COMMISSIONER FOR PATENTS: Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):									
				ame under 31	CPK I.	130(a):			
One n	nonth of origina	al due da	ate (\$120.00)						
☐ Ţwon	nonths of origin	iai due d	ate (\$450.00) date (\$1,020.00	`				ì	
	months of origi	ppiai uue nal due i	date (\$1,590.00)	,				1	
⊠ Five r	nonths of origin	nal due d	date (\$2,160.00)					Ì	
	se in connectio	n with th	e matter for which	h this extensi	on is rec	uested:			
	d herewith.								
☐ has b	een filed.								
☐ The n	esponse is the	filing of	a continuing app	lication, the pr	ior appli	ication hav	ing an	express	
ahand	donment condi	tioned or	n the granting of	a filino date to	the cor	itinuing apr	dication	າ. ໄ	
			de amended clai						
	mpanying pape	ers inclu	de amended clai		which h	as been ca	lculate	d as follows:	
			CLAIMS AS A						
(1)	(2)	(3)	(4)	(5)		(6)		(7) Additional	
	Claims		Highest number Previously paid	No. of Ext		Rate		Fee	
	remaining After		for	Ciairis pres		itale		, 00	
	amendment		101	1					
Total Claims	12	Minus	20 =	0	,	x \$50	-	\$ 0.00	
Indep. Claims	6	Minus	4 =	2		k \$200	=	\$ 400.00	
☐ First Appearar	nce of a multip	le depen	dent claim			+ \$360	=	\$ 0.00	
			Additional Fee for		ent			\$400.00	
* If the entry in c	olumn 2 is less the	an the entr	y In column 4, write IN THIS SPACE is	'0" in column 5. less than 20. writ	te "20" in 1	ihis space.			
*** If the "Highest i	Number Previous	y Paid For	" IN THIS SPACE is	less than 3, write	: "3" in this	s space.			
The "Highest N	lo. Previously Paid	For (Total	al or Indep.) is the hi	ghest number fou	ınd in the	appropriate b	ox in Col	1. of a prior	
amendment or the number of claims originally filed.									
☐ The following other fees are incurred by the accompanying papers.									
Other:									
Please charge Deposit Account No. 09-0089 in the name of Immunex Corporation in the amount of \$2,560.00. A duplicate copy of this petition is attached.									
☑ The Commissioner is hereby authorized to charge any additional fees which may be required by the									
accompanying papers, or credit any overpayment to Deposit Account No. 09-0089.									
Please Send Future Correspondence To:									
22932 Led luquing									
Immunex Corporation Scott L. Ausenhus									
Law Department Attorney/Agent for Applicant(s)									
1201 Amgen Court West Registration No.: 42,271 Seattle, Washington 98119-3105 Phone: (206) 265-7858									
	(208) 265-7000 Date: April 20, 2007								
Manay 200 1000									

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being	attached or enclosed) is being facsimile transmitte	ed to the United
States Patent and Trademark Office on the date shown below:	Dilata	
A TAG ADDT	1 A 1 1 Y / 1 A 1 X / A	

Date

Amendment dated April 20, 2007 Response to Restriction Requirement mailed 10/23/2006

APR 2 0 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.:

2852-US-CNT

Dirk M. ANDERSON

Group Art Unit: 1646

Serial No: 10/802,133

Examiner:

Eileen B. O'Hara

Filed:

March 16, 2004

For:

ANTIBODIES AGAINST RANK LIGAND (AS AMENDED)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

This paper is filed in response to the Restriction Requirement mailed October 23, 2006, which set November 23, 2006 as the original deadline for submitting a response. A petition for a five month extension of time is enclosed, thus extending the deadline for submitting a response until April 23, 2007. Accordingly, this response is timely filed. Please amend this application as follows:

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.
- Remarks/Arguments begin on page 5 of this paper.

04/23/2007 TL0111

00000029 090089

10802133

01 FC:1201 02 FC:1255

400.00 DA 2160.00 DA